Amarin (NASDAQ:AMRN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Amarin (NASDAQ:AMRN - Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company's stock.

Amarin Price Performance

Shares of Amarin stock traded up $0.00 during trading hours on Friday, hitting $0.46. The company's stock had a trading volume of 626,655 shares, compared to its average volume of 1,388,423. The company has a market capitalization of $188.91 million, a PE ratio of -5.11 and a beta of 1.82. Amarin has a 12 month low of $0.35 and a 12 month high of $1.11. The stock has a 50 day moving average of $0.54 and a 200 day moving average of $0.54.

Amarin's stock is set to reverse split on Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, April 10th.

Amarin (NASDAQ:AMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The business had revenue of $62.31 million during the quarter, compared to analyst estimates of $32.37 million. Equities analysts expect that Amarin will post -0.15 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund acquired a new stake in Amarin in the 4th quarter valued at about $68,000. Waterfront Wealth Inc. lifted its position in shares of Amarin by 181.4% in the fourth quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock valued at $1,204,000 after buying an additional 1,599,956 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company's stock worth $816,000 after acquiring an additional 104,939 shares during the period. Arkfeld Wealth Strategies L.L.C. increased its holdings in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 20,000 shares during the last quarter. Finally, LCM Capital Management Inc raised its stake in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after acquiring an additional 25,100 shares during the period. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.